患有胰岛素受体突变的患者的超胰岛素性低血糖症
Marcus Imamovic1,2, Mattias Vågberg3,4, Kristina Cederquist3,4
1Department of Medicine, University Hospital of Umeå, 901 85 Umeå, Sweden.
JCEM case reports
|December 11, 2024
概括
胰岛素受体 (INSR) 基因中的罕见遗传变异会导致高胰岛素性低血糖症. 本案例研究详细介绍了治疗成功的成人发病INSR相关的低血糖症的lanreotide后的二氧化物不耐受.
科学领域:
- 内分泌学 在内分泌学.
- 医学遗传学 医学遗传学
背景情况:
- 超胰岛素性低血糖是一种罕见的疾病,由影响胰岛素调节的遗传变异引起.
- 胰岛素受体 (INSR) 基因变异是这些疾病的不常见但重要的原因.
研究的目的:
- 报告因INSR基因变异引起的成年期高胰岛素性低血糖病例.
- 讨论这种罕见疾病的诊断方法和治疗管理.
主要方法:
- 在成年男性中,复发性餐后低血糖的临床表现.
- 内分泌评估,包括胰岛素与C-的比例.
- 一个低血糖基因组的下一代测序,识别INSR变体 (c.3079C > T, p.
主要成果:
- 患者出现了复发的餐后低血糖症.
- 基因分析揭示了INSR基因中的异合无意义变异.
- 治疗diazoxide最初改善了症状,但由于副作用被切换到lanreotide,保持正常血糖.
结论:
- 在高胰岛素性低血糖症的差异诊断中,即使在成人患者中,也应该考虑INSR基因的遗传变异.
- 兰胺可以成为与INSR相关的胰岛素过高血糖症的有效治疗选择,特别是在无法耐受氧化物时.
相关概念视频
Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
Insulin: Dosing Regimen and Adverse Effects
145
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
145
Oral Hypoglycemic Agents: Glinides
139
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
139
Insulin: The Receptor and Signaling Pathways
1.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.1K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.1K
Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298


